4 - Azitra, Inc. (0001701478) (Issuer)

4 - Azitra, Inc. (0001701478) (Issuer)

8-K - Azitra, Inc. (0001701478) (Filer)

10-Q - Azitra, Inc. (0001701478) (Filer)

RW - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

S-1 - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

10-Q - Azitra, Inc. (0001701478) (Filer)

424B3 - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended September 30, 2025, and provided a business update. Q3 2025 and Recent Business Highlights Dosed first patient in Phase 1/2 trial for ATR-04 program targeting oncology patients with EGFRi-associated rash in August 2025Presented positive preclinical data at BIO-Europe® for ATR-01 program, targeting the treatment of ichthyosis vulg

BRANFORD, Conn., Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has come to the Company's attention that a report has been circulated claiming that the Company priced a $44 million registered direct offering. This report is false and should not be relied upon. Azitra urges investors, stakeholders, and the public to rely only on information formally issued by the Company through its official channels. The Company is taking steps to ide

ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgaris Preclinical data show production of active, functional filaggrin delivered through human stratum corneum and repair of damaged model skin Further details to be presented in virtual presentation at BIO-Europe ® BRANFORD, Conn., Oct. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, Travis Whitfill, PhD, MPH, will present positive preclinical progress for its ATR-01 program, targeting the treatment of ic

BRANFORD, Conn., Oct. 15, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Travis Whitfill Ph.D., Co-Founder and Chief Operating Officer will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit, which is being held at the Hard Rock Hotel in New York City, October 22-23, 2025. The panel members will discuss Netherton syndrome and Recessive Epidermolysis Bullosa (RDEB), two categories with novel therapeutic approaches spannin

BRANFORD, Conn., Oct. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. Section 1003(a)(ii) requires a listed company to have stockholders' equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Azitra is subject to the procedures and requiremen

BRANFORD, Conn., Sept. 4, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, Travis Whitfill PhD MPH, will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City. In the prerecorded presentation, Mr. Whitfill will highlight recent updates and progress with Azitra's pipeline including the announcement of promising

BRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the dosing of the first patient in its Phase 1/2 clinical trial of ATR04-484, a topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. annually. "Dosing the first patient

Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025 BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 6.66 pre-split shares. The reverse stock split will become effective at 12:01 A.M. Eastern Time, on August 21, 2025. The Company's common stock will continue to be traded on the NYSE American under the symbol "AZTR" and will begin trading on a split-adjusted basis when the market opens on August 21, 2025. The

Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application siteTrial is 50% enrolled; six patients have received ATR12-351, a live precision dermatology therapeutic candidate Azitra presenting at the 2025 BIO International ConventionBRANFORD, Conn., June 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced encouraging safety data from the initial clinical trial of its live biotherapeutic candidate, ATR12-351, targeting Netherton syndrome.

BRANFORD, Conn., June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the company will present at the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome and ATR-04, in development for the treatment of moderate to severe EGFRi-associ

BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres

Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the third quarter ended September 30, 2023. Q3 and Recent Business Highlights Advanced its pipeline programs including ATR-12 (Netherton syndrome), ATR-04 (EGFRi-associated rash) and its Joint Development Agreement with Bayer Completed and filed post-IND, FDA commitments for characterization of drug product for ATR-12 Selected and hired clinical research organization for ATR-12 clinical trial. Selected initial sites for activation Francisco Salva, Chief Executive Officer of Azitra, commented: "During t

SC 13G/A - Azitra, Inc. (0001701478) (Subject)

SC 13G/A - Azitra, Inc. (0001701478) (Subject)

SC 13G/A - Azitra, Inc. (0001701478) (Subject)

SC 13D/A - Azitra, Inc. (0001701478) (Subject)

SC 13G - Azitra, Inc. (0001701478) (Subject)

SC 13G - Azitra, Inc. (0001701478) (Subject)

SC 13G - Azitra, Inc. (0001701478) (Subject)

SC 13G/A - Azitra, Inc. (0001701478) (Subject)

SC 13G - Azitra, Inc. (0001701478) (Subject)